iProteos focuses its activity on developing new therapeutic strategies based on modulation of protein-protein interactions (PPIs) or protein-ligand interactions (PLI). Specifically, iProteos apply the IPRO technology to search for therapeutic agents treating diseases of the central nervous system (CNS). Based on its expertise, iProteos would be your perfect partner for the discovery of potent and active peptidomimetics for your own targets.
iProteos – peptidomimetics experts
iProteos focus its research on new mechanism of action for CNS diseases, like cognitive impairment associated with Schizophrenia (CIAS), Parkinson’s Disease (PD) or Epilepsy. Iproteos has developed a proprietary technology (IPRO Technology) to modulate challenging targets by disruption of either protein-protein or protein-ligand complexes involved in disease progression. iProteos apply its own IPRO technology to search for therapeutic agents for the treatment of CNS’s diseases, where a deregulation of a PPI could be restored to normal levels through the action of a peptide ligand. Technologies and iProteos’s expertise allow this biotech company to quickly and efficiently discover new peptidomimetic drugs for several targets. The main features of peptidomimetics synthesized with IPRO technology are high specificity, high permeability to biological barriers (such as the blood-brain barrier (BBB) or the gastrointestinal tract (GIT)), optimized ADME properties, reduced toxicity and reduced or total absence of immunogenicity.
iProteos’s business model comprises discovering, pre-clinical validation, patenting and licensing of new peptidomimetic drugs. Teresa Tarrago and Ernest Giralt are the co-founders of Iproteos. The 2014 Expoquimia prize in the Biotechnology’s category has been awarded to Iproteos for researches concerning “IPR19: a new drug for the treatment of the cognitive impairment associated with schizophrenia”.
More about iProteos : http://www.iproteos.com/
iProteos – peptidomimetics – peptidomimetic drugs – IPRO technology – protein-protein interactions – PPIs – protein-ligand interactions – PLI – Schizophrenia – Parkinson’s Disease – PD – Epilepsy – peptides
iProteos – peptidomimetic – IPR19 – Teresa Tarrago – Ernest Giralt – IPRO – permeability biological barriers – blood-brain barrier – BBB – gastrointestinal tract – GIT – cognitive impairment associated with Schizophrenia – CIAS – CNS diseases – peptide